China aims to become a leading player in the fast-growing biotechnology sector by capitalising on research costs that are one fifth those of Europe or the United States, a top official said on Monday.
In the past, the country’s drug industry has largely consisted of manufacturing cheap generics and producing traditional Chinese medicine.
Now the government is making biotechnology a priority, Professor Wang Hongguang, director general of the China National Center for Biotechnology Development, told a pharmaceutical conference in London.
CDT EBOOKS
Subscribe to CDT
SUPPORT CDT
Giving Assistant
Anti-censorship Tools
Click on the image to download Firefly for circumvention
